Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial

DSpace Repository

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial

Author: Ascierto, Paolo A.; Dummer, Reinhard; Gogas, Helen J.; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion-Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B.; Yamazaki, Naoya; Loquai, Carmen; Robert, Caroline; Flaherty, Keith T.
Tübinger Autor(en):
Garbe, Claus
Published in: Journal of Clinical Oncology (2023), Bd. 41, H. 29, S. 4621-4631
Verlagsangabe: Philadelphia : Lippincott Williams & Wilkins
Language: English
Full text: http://dx.doi.org/10.1200/JCO.22.02322
ISSN: 0732-183X
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)